Target intelligence / Profile preview

Human mesenchymal stem cell (MSC)

Target
MSC
Molecular classification
Other (Cell type)
01

Overview

Human mesenchymal stem cells (MSCs) are multipotent progenitor cells capable of differentiating into osteoblasts, adipocytes, and chondrocytes. MSC fate and function are tightly regulated by the extracellular matrix (ECM) microenvironment, which provides critical biochemical and biomechanical cues. These signals are transmitted through cell surface receptors such as integrins, activating intracellular signaling pathways (e.g., ERK/MAPK, FAK, YAP/beta-catenin) that determine proliferation, differentiation, and tissue repair capacity. MSCs and their interactions with the ECM are central to tissue regeneration and are being explored in diverse therapeutic settings, but neither MSCs nor the ECM are themselves conventional single-molecule drug targets. Rather, the ECM functions as a dynamic regulatory platform that influences cell behavior and therapy outcomes.

Other names
Mesenchymal stromal cellbone marrow stromal cellmultipotent mesenchymal stromal cellmarrow stromal cell
02

Mechanism of action

Not applicable in the conventional sense. When used therapeutically, MSCs function via paracrine signaling, immunomodulation, and supporting tissue repair. In regenerative medicine, the ECM microenvironment influences their fate via signal transduction through integrins and growth factor receptors (e.g., ERK/MAPK pathways).

03

Biological functions

Cell proliferationDifferentiation (adipogenic, osteogenic, chondrogenic)Regulation of tissue repair and regenerationImmunomodulationECM production and remodeling
04

Disease associations

Tissue regeneration (e.g., bone, cartilage, fat)Cancer (role in tumor microenvironment modulation)Inflammation (immunomodulatory effects)FibrosisOther regenerative medicine applications
05

Safety considerations

Tumorigenicity (potential to promote or modulate tumors in certain settings)Immune rejection or undesired immunomodulationHeterogeneity in cell preparationsThrombosis or embolic risk when infused systemically in clinical trials
06

Interacting drugs

FGF-2

2 more in the full profile.

07

Biomarkers

CD73CD90CD105 (positive markers for MSCs)Lack of hematopoietic markers (e.g., CD34-, CD45-)Integrin expression (e.g., integrin α2β1, α11β1)

Beyond the preview

Go deeper on Human mesenchymal stem cell (MSC).

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Drug pipeline

Full profile access

Explore the programs pursuing this target and their development progress.

  • Drug candidates
  • Developers
  • Development stage

Clinical trials

Full profile access

Follow the clinical studies evaluating therapies directed at this target.

  • Trial design
  • Status
  • Readouts

Competitive landscape

Full profile access

Compare approaches across drug candidates, modalities, and indications.

  • Programs
  • Modalities
  • Indications

Literature & evidence

Full profile access

Investigate the research and source evidence behind target biology and development.

  • Publications
  • Sources
  • Analysis

Patents

Full profile access

Explore patent activity around therapies and technologies addressing this target.

  • Patents
  • Assignees
  • Technologies

Research & analysis

Full profile access

Connect target biology, drug development, and emerging evidence in your research.

  • Biology
  • Development news
  • Analysis

Bring the full picture into focus.

See how Gosset can support your research on Human mesenchymal stem cell (MSC).

Explore the full profile

Gosset Free

Get started with Gosset.

Enter your work email and we’ll be in touch with next steps.

Work email preferred.

Book a call